Divi's Laboratories share price
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.
- Next results date: the board meets on 7 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,37,594 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 1 Aug 2026
- 81.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 14.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 1 Aug 2026
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 1 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,20,26160.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 1 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3,080 Crup 8.80%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹902 Crup 20.11%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 29.3%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 9 Nov | Dec 2024Filed 3 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 6 Aug | Sep 2025Filed 7 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 27 May | Jun 2026Filed 1 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Net profit | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 21.8% | 25.4% | 25.6% | 22.6% | 25.4% | 22.4% | 26.5% | 29.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 93% of 2,480 trading days over the last 10 years.
At or below today's level on 96% of 1,980 trading days since Oct 2018.
At or below today's level on 93% of 1,980 trading days since Oct 2018.
At or below today's level on 11% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +3.5% | +17.2% | −12.2% | 0.5% |
| 3 years | +28.8% | +12.1% | +14.4% | 0.6% |
| 5 years | +11.1% | +5.3% | +4.9% | 0.7% |
Mutual funds holding it
410 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 127 of the 198 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 5 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 15
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 17
- AddedAdded. Funds that held more shares than at the end of the month before.
- 121
- CutCut. Funds that held fewer shares than at the end of the month before.
- 77
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 175
| Fund | |||
|---|---|---|---|
 SBI Large Cap FundSBI Mutual Fund | 20,32,024 | 3.61% | ₹1,888.1 Cr |
 HDFC Flexi Cap FundHDFC Mutual Fund | 18,93,863 | 1.62% | ₹1,759.7 Cr |
| SBI Aggressive Hybrid FundSBI Mutual Fund | 17,00,000 | 1.83% | ₹1,579.6 Cr |
| SBI Focused FundSBI Mutual Fund | 13,00,000 | 2.41% | ₹1,207.9 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 8,93,550 | 2.74% | ₹830.2 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 8,88,857 | 0.81% | ₹825.9 Cr |
| Axis Large Cap FundAxis Mutual Fund | 8,56,121 | 2.72% | ₹795.5 Cr |
| SBI Multicap FundSBI Mutual Fund | 8,50,000 | 3.37% | ₹789.8 Cr |
| SBI Large & Midcap FundSBI Mutual Fund | 8,30,000 | 1.90% | ₹771.2 Cr |
 Nippon India Large Cap FundNippon India Mutual Fund | 8,00,190 | 1.45% | ₹743.5 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Divi's Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,19,404 | 34.7 | 5.0 | 23.1 | +11.4% | +16.6% | 15.5% | 16.9% | 0.92% |
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 25 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 2 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 11 Aug 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 11 Aug 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 17 Aug 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹20.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Aug 2026
Jul 2026
31 Jul · Retirement
24 Jul · Analysts
Divi's Laboratories share price by year
Each calendar year to 2025.Divi's Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 6,392.50 | +4.8% | 6,983.50 | 5,258.95 |
| 2024 | 6,098.80 | +56.2% | 6,256.50 | 3,367.85 |
| 2023 | 3,903.90 | +14.4% | 3,939.95 | 2,750.85 |
| 2022 | 3,413.20 | −27.0% | 4,651.25 | 3,265.95 |
| 2021 | 4,678.20 | +21.8% | 5,372.15 | 3,272.90 |
| 2020 | 3,841.90 | +108.1% | 3,841.90 | 1,805.25 |
| 2019 | 1,845.80 | +24.5% | 1,860.65 | 1,437.90 |
| 2018 | 1,482.65 | +35.0% | 1,562.25 | 990.80 |
| 2017 | 1,098.35 | +40.1% | 1,123.45 | 545.30 |
| 2016 | 783.70 | −32.1% | 1,347.85 | 762.30 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 9,165.00 | 9,175.50 | 8,797.00 | 8,950.00 | 8,904.51 | 6,20,261 | 60.6% |
| 22 Oct 2026 | 9,114.00 | 9,190.00 | 9,006.50 | 9,162.00 | 9,103.23 | 10,40,584 | 76.1% |
| 21 Oct 2026 | 9,190.00 | 9,243.00 | 9,041.00 | 9,190.00 | 9,130.61 | 6,85,478 | 70.9% |
| 19 Oct 2026 | 9,191.50 | 9,323.50 | 9,045.00 | 9,087.00 | 9,175.76 | 4,48,972 | 54.0% |
| 16 Oct 2026 | 9,030.50 | 9,248.00 | 8,985.50 | 9,144.50 | 9,099.20 | 7,78,528 | 61.8% |
| 15 Oct 2026 | 9,085.00 | 9,124.50 | 8,950.00 | 9,030.00 | 9,036.58 | 6,45,244 | 65.6% |
| 14 Oct 2026 | 9,315.00 | 9,315.00 | 8,937.50 | 9,023.00 | 9,069.38 | 9,92,022 | 68.1% |
| 13 Oct 2026 | 9,411.00 | 9,423.50 | 9,164.50 | 9,285.00 | 9,248.72 | 4,16,650 | 58.8% |
| 12 Oct 2026 | 9,346.00 | 9,431.50 | 9,297.00 | 9,426.00 | 9,378.01 | 3,58,499 | 62.4% |
| 9 Oct 2026 | 9,417.00 | 9,460.50 | 9,273.00 | 9,340.00 | 9,343.19 | 3,78,861 | 58.3% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 23 Dec 2016 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 23 Sep 2015 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 30 Jul 2009 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 3 Aug 2007 | Split | 0.2000 | Each share became 5. |
About Divi's Laboratories
Divi's Laboratories Limited makes active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients. Its customers are pharmaceutical and nutraceutical companies across the globe. It was incorporated in 1990 and is headquartered in Hyderabad, India.
The business is organised into three portfolios: generic APIs, custom synthesis and nutraceuticals. The generic API business focuses on a chosen set of molecules. Custom synthesis is contract manufacturing of complex APIs and intermediates for global innovator companies. Nutraceuticals covers carotenoid ingredients and finished formulations, which include fat soluble vitamins, for food, beverage, dietary supplement and feed manufacturers.
The company has three manufacturing facilities. Unit 1 is at Lingojigudem village in Yadadri Bhuvanagiri, Telangana. Unit 2 is at Chippada village in Visakhapatnam district, Andhra Pradesh. Unit 3 is at Ontimamidi village in Kakinada district, Andhra Pradesh, and has operated since January 2025. Research is carried out at the Divi's Research Center in Sanath Nagar, Hyderabad, and at process development centres at its manufacturing facilities. The company has a presence in more than 100 countries. It has two wholly owned subsidiaries, in New Jersey in the United States and in Basel in Switzerland, which support the marketing of its nutraceutical products.
Dr. Murali K. Divi, the Managing Director, is listed as a promoter. A promoter is the person or group that set up a company or controls it. The shares of the company are listed on the National Stock Exchange of India and BSE Limited.
- Legal name
- Divi's Laboratories Limited
- NSE symbol
- DIVISLAB
- BSE code
- 532488
- ISIN
- INE361B01024
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Mar 2003
- Face value
- ₹2
- CIN
- L24110TG1990PLC011854
- Corporate identity number, the registrar of companies' code for it